Results 61 to 70 of about 5,279 (205)

Paxlovid. Arabic

open access: yes, 2021
Title from PDF caption (viewed on January 4, 2022)."OHA4029B12292021 ARABIC"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.

core  

Population-Based Propensity Score-Matched Analysis of Paxlovid and Molnupiravir Effectiveness in High-Risk COVID-19 Patients

open access: yesInternational Journal of Infectious Diseases
Introduction: COVID-19 poses a severe threat to high-risk populations, such as the elderly and those with incomplete vaccination. Despite the availability of treatments like Paxlovid and Molnupiravir, their relative effectiveness in preventing severe ...
Dr Yi-hsuan Chen   +4 more
doaj   +1 more source

Sigma‐1 Receptor‐Targeting Compounds Show Antiviral Activity Across Multiple Coronavirus Models

open access: yesJournal of Medical Virology, Volume 98, Issue 10, October 2026.
ABSTRACT Over the past two decades, coronaviruses have caused three major public health crises, including the epidemics of SARS‐CoV, MERS‐CoV, and SARS‐CoV‐2. Following the outbreak of SARS‐CoV‐2, several antiviral drugs have been approved for the treatment of COVID‐19.
Cuiling Zhang   +9 more
wiley   +1 more source

Paxlovid. Russian

open access: yes, 2021
Title from PDF caption (viewed on January 4, 2022)."OHA4029B12292021 RUSSIAN"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program. It is for informational purposes and may

core  

Pulmonary Herpes Simplex Virus Reactivation in Invasively Mechanically Ventilated Patients With COVID‐19 in Intensive Care Unit

open access: yesJournal of Medical Virology, Volume 98, Issue 10, October 2026.
ABSTRACT Patients in intensive care units (ICU) under mechanical ventilation, particularly those with SARS‐CoV‐2 infection, are highly susceptible to Herpes simplex virus (HSV) reactivation. Given the lack of data on the SARS‐CoV‐2 Omicron and Delta variants, this study aimed to assess the prevalence of pulmonary HSV reactivation in mechanically ...
Bastien Zarlenga   +14 more
wiley   +1 more source

Paxlovid. Korean

open access: yes, 2021
Title from PDF caption (viewed on January 4, 2022)."OHA4029B12292021 KOREAN"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.

core  

Paxlovid. Spanish

open access: yes, 2021
Title from PDF caption (viewed on January 4, 2022)."OHA4029B12292021 SPANISH"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program. It is for informational purposes and may

core  

Should Paxlovid be prescribed for patients with severe COVID‐19 in the late course of infection? A case report

open access: yesMedicine Advances, 2023
The infection of the coronavirus disease 2019 (COVID‐19) is often accompanied by pneumonia with both high incidence and mortality. Paxlovid is commonly prescribed in patients with mild and normal pneumonia within 5 days from the symptom onset. Herein, we
Qiang Li   +15 more
doaj   +1 more source

Model‐Based Tacrolimus Dosing Using the Population Pharmacokinetic Analysis Under the Nirmatrelvir/Ritonavir Therapy

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 9, September 2026.
ABSTRACT Nirmatrelvir/ritonavir is an antiviral agent used against severe acute respiratory syndrome coronavirus 2 infection and inhibits cytochrome P450 3A and P‐glycoprotein. The concomitant use of nirmatrelvir/ritonavir markedly increases tacrolimus blood concentrations. Although temporary discontinuation or dose reduction of tacrolimus at the start
Kotaro Itohara   +14 more
wiley   +1 more source

Paxlovid. Vietnamese

open access: yes, 2021
Title from PDF caption (viewed on January 4, 2022)."OHA4029B12292021 VIETNAMESE"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.

core  

Home - About - Disclaimer - Privacy